AU2007325280B2 - Combination of IAP inhibitors and FLT3 inhibitors - Google Patents

Combination of IAP inhibitors and FLT3 inhibitors Download PDF

Info

Publication number
AU2007325280B2
AU2007325280B2 AU2007325280A AU2007325280A AU2007325280B2 AU 2007325280 B2 AU2007325280 B2 AU 2007325280B2 AU 2007325280 A AU2007325280 A AU 2007325280A AU 2007325280 A AU2007325280 A AU 2007325280A AU 2007325280 B2 AU2007325280 B2 AU 2007325280B2
Authority
AU
Australia
Prior art keywords
alkyl
aryl
ethyl
cyclohexyl
propionamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007325280A
Other languages
English (en)
Other versions
AU2007325280A1 (en
Inventor
James Douglas Griffin
Leigh Zawel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Dana Farber Cancer Institute Inc
Original Assignee
Novartis AG
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Dana Farber Cancer Institute Inc filed Critical Novartis AG
Publication of AU2007325280A1 publication Critical patent/AU2007325280A1/en
Application granted granted Critical
Publication of AU2007325280B2 publication Critical patent/AU2007325280B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007325280A 2006-11-28 2007-11-27 Combination of IAP inhibitors and FLT3 inhibitors Ceased AU2007325280B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86744806P 2006-11-28 2006-11-28
US60/867,448 2006-11-28
US89108807P 2007-02-22 2007-02-22
US60/891,088 2007-02-22
PCT/US2007/085579 WO2008067280A2 (en) 2006-11-28 2007-11-27 Combination of iap inhibitors and flt3 inhibitors

Publications (2)

Publication Number Publication Date
AU2007325280A1 AU2007325280A1 (en) 2008-06-05
AU2007325280B2 true AU2007325280B2 (en) 2011-03-10

Family

ID=39386468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007325280A Ceased AU2007325280B2 (en) 2006-11-28 2007-11-27 Combination of IAP inhibitors and FLT3 inhibitors

Country Status (20)

Country Link
US (1) US8492429B2 (https=)
EP (1) EP2089024B1 (https=)
JP (1) JP5394249B2 (https=)
KR (1) KR20090087094A (https=)
AT (1) ATE509629T1 (https=)
AU (1) AU2007325280B2 (https=)
BR (1) BRPI0719543A2 (https=)
CA (1) CA2670498A1 (https=)
CO (1) CO6210722A2 (https=)
EC (1) ECSP099472A (https=)
GT (1) GT200900142A (https=)
IL (1) IL198551A0 (https=)
MA (1) MA30966B1 (https=)
MX (1) MX2009005621A (https=)
NO (1) NO20092417L (https=)
PL (1) PL2089024T3 (https=)
PT (1) PT2089024E (https=)
RU (1) RU2456983C2 (https=)
TN (1) TN2009000206A1 (https=)
WO (1) WO2008067280A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US9750729B2 (en) * 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
CA2850330A1 (en) 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
PH12021551985A1 (en) 2019-02-22 2022-08-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EA202191984A1 (ru) 2019-02-22 2021-11-19 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2007075525A2 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1453661A1 (ru) * 1972-11-17 1989-10-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Противоопухолевое средство "продимин
WO2004005248A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097791A1 (en) * 2004-04-07 2005-10-20 Novartis Ag Inhibitors of iap
WO2007075525A2 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
WO2008016893A1 (en) * 2006-08-02 2008-02-07 Novartis Ag Smac peptidomimetics useful as iap inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Blood (2007) 109(3) pp 1220-1227 *
Journal of Biological Chemistry (2002) 277(46) pp 44236-44243 *
Molecular Cancer Therapeutics (2007) 6(7) pp 1951-1961 *

Also Published As

Publication number Publication date
MX2009005621A (es) 2009-06-12
RU2009124590A (ru) 2011-01-10
PL2089024T3 (pl) 2011-10-31
US8492429B2 (en) 2013-07-23
JP2010511059A (ja) 2010-04-08
BRPI0719543A2 (pt) 2014-02-25
AU2007325280A1 (en) 2008-06-05
JP5394249B2 (ja) 2014-01-22
ECSP099472A (es) 2009-10-30
WO2008067280A3 (en) 2008-08-07
PT2089024E (pt) 2011-08-31
CO6210722A2 (es) 2010-10-20
RU2456983C2 (ru) 2012-07-27
EP2089024A2 (en) 2009-08-19
NO20092417L (no) 2009-08-25
TN2009000206A1 (en) 2010-10-18
WO2008067280A2 (en) 2008-06-05
GT200900142A (es) 2010-06-24
IL198551A0 (en) 2010-02-17
US20100056467A1 (en) 2010-03-04
KR20090087094A (ko) 2009-08-14
CA2670498A1 (en) 2008-06-05
MA30966B1 (fr) 2009-12-01
EP2089024B1 (en) 2011-05-18
ATE509629T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
AU2007325280B2 (en) Combination of IAP inhibitors and FLT3 inhibitors
Mo et al. Human ABCG2: structure, function, and its role in multidrug resistance
AU2007342225A1 (en) Use of IAP inhibitors for the treatment of acute myeloid leukemia
MX2008012728A (es) Combinaciones de agentes terapeuticos para el tratamiento de cancer.
PT1441737E (pt) Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
US12433867B2 (en) Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
KR20210002015A (ko) Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
EP1638574B1 (en) New pharmaceutical uses of staurosporine derivatives
AU2006236812A1 (en) Combinations, methods and compositions for treating cancer
KR20080038298A (ko) 아미노피리미딘 조절제 및 파네실 전이 효소 억제제를이용하는 ｆｌｔ３ 키나아제의 상승적 조절
von Mehren New therapeutic strategies for soft tissue sarcomas
ES2366299T3 (es) Combinación de inhibidores de iap e inhibidores flt3.
MX2008012716A (es) Combinaciones de agentes terapeuticos para el tratamiento de cancer.
ES2549327T3 (es) Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis
JP2007510671A (ja) アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物
AU2005279344B2 (en) Use of midostaurin for treating gastrointestinal stromal tumors
CA2615598C (en) Compositions for treatment of systemic mastocytosis
US20060252714A1 (en) Pharmaceutical compositions and methods for treating multidrug resistant cancer
HK1095519B (en) The use of staurosporine derivatives for the manufacture of a medicament

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired